Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer.

ABSTRACT:

Background

The benefits of continuing immunotherapy beyond disease progression in advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) remain uncertain, along with the specific patient subgroups that may gain the most from this approach. This retrospective study aims to evaluate the efficacy of this approach and identify target patient populations likely to benefit.

Methods

We collected data from patients with NSCLC and SCLC who experienced disease progression following initial immune checkpoint inhibitor (ICI) treatment from January 2020 to December 2023. Patients were categorized based on second-line treatment: those receiving immunotherapy beyond progression (IBP) and those receiving non-immunotherapy beyond progression (NIBP). Survival outcomes a

SUBMITTER: Cheng J 

PROVIDER: S-EPMC11861770 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature